[Inhibition of iron-catalyzed oxidative reactions restores mathcing between coronary blood flow and myocardial metabolic demand in type 2 diabetes].
In diabetes, endothelium-dependent dilation of large and small coronary arteries is impaired, which results in a mismatch between myocardial metabolic demand and coronary blood flow. It has been proved that deferoxamine, an iron chelator that inhibits Fenton and Haber-Weiss reactions, restores a normal response to cold pressor test and flow increase in angiographically normal epicardial coronary arteries of diabetic patients. This result suggests that nitric oxide could be inactivated by reactive oxygen species. The aim of this study was to assess the effects of deferoxamine on coronary microcirculation vasomotion when myocardial oxygen demand is increased by sympathetic stimulation elicited by cold pressor test in type 2 diabetic patients. In 17 patients with angiographically normal coronary arteries and without any other coronary risk factors, coronary blood flow has been measured using quantitative angiography and intracoronary Doppler at baseline and during a cold pressor test, before and after intravenous administration of 500 mg deferoxamine. Increase in rate-pressure product, an estimate of myocardial metabolic demand, was similar before and after deferoxamine (+21.1 +/- 8.7% vs +20.5 +/- 8.9%, respectively), but coronary blood flow increase was significantly higher after deferoxamine (+6.3 +/- 12.9% vs +31.8 +/- 16.7%, respectively, p < 0.001), and coronary resistance was increased before deferoxamine and decreased after (+14.8 +/- 21.9% vs -7.9 +/- 10.9%, respectively, p < 0.001). Moreover, before deferoxamine, the negative correlation between coronary blood flow and rate-pressure product changes before deferoxamine (R = 0.518, P < 0.05) was turned in a positive relationship after deferoxamine (r = 0.546, p < 0.05). In conclusion, in type 2 diabetic patients, endothelium-dependent dilation of the coronary microcirculation is restored when iron-catalysed oxidative reactions are inhibited by deferoxamine, which restores the normal matching between myocardial oxygen demand and coronary blood flow.
Nitenberg
A
A
Service de physiologie et d'explorations fonctionnelles, hôpital Louis-Mourier, CHU Xavier-Bichat, Colombes.
Ledoux
S
S
Valensi
P
P
Sachs
R
R
Antony
I
I
D000328:Adult; D002614:Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology; D003331:Coronary Vessels / Q000502:physiology; D003676:Deferoxamine / Q000008:administration & dosage / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000473:pathology; D004727:Endothelium / Q000502:physiology; D005260:Female; D006321:Heart / Q000502:physiology*; D006439:Hemodynamics; D006801:Humans; D007501:Iron / Q000494:pharmacology*; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D018384:Oxidative Stress; D017382:Reactive Oxygen Species; D012039:Regional Blood Flow
D002614:Chelating Agents; D017382:Reactive Oxygen Species; D007501:Iron; D003676:Deferoxamine